Trends in Cardiovascular Medicine
Volume 15, Issue 7 , Pages 237-243 , October 2005

The RAGE Axis and Endothelial Dysfunction: Maladaptive Roles in the Diabetic Vasculature and Beyond

  • Ravichandran Ramasamy
    • ,
  • Shi Fang Yan
    • ,
  • Ann Marie Schmidt

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Ann Marie Schmidt, Division of Surgical Science, Department of Surgery, Columbia University Medical Center, 630 West 168th St, P&S 17-501, New York, NY 10032, USA. Tel.: (+1) 212-305-6406; fax: (+1) 212-305-5337.

References 

  1. Ahmed N, Thorn alley PJ. Quantitative screening of protein biomarkers of early gyration, advanced gyration, oxidation and intonation in cellular and extracellular proteins by tandem mass spectrometry multiple reaction monitoring. Biochem Soc Trans. 2003;31:1417–1422
  2. Aso Y, Iuka T, Tehama K, Taciturn Y. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol. 2000;37:87–92
  3. Basta G, Lazzerini G, Del Turco S, et al. At least two pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation endproducts. Arterioscler Thromb Vasc Biol. 2005;25:1401–1407
  4. Bolton WK, Cattran DC, Williams ME, et al. Randomized trial of an inhibitor of formation of advanced glycation endproducts in diabetic nephropathy. Am J Nephrol. 2004;24:32–40
  5. Bucciarelli LG, Wendt T, Qu W, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E null mice. Circulation. 2002;106:2827–2835
  6. Chavakis T, Bierhaus A, Al-Fakhri N, et al. The pattern recognition receptor (RAGE) is a counter receptor for leukocyte integrins: A novel pathway for inflammatory cell recruitment. J Exp Med. 2003;198:1507–1515
  7. Chen Y, Yan SS, Colgan J, et al. Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol. 2004;173:1399–1405
  8. Cipollone F, Iezzi A, Fazia M, et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: Role of glycemic control. Circulation. 2003;108:1070–1077
  9. Falcone C, Campo I, Emanuele E, et al. Relationship between the -374 T/A RAGE gene polymorphism and angiographic coronary artery disease. Int J Mol Med. 2004;14:1061–1064
  10. Falcone C, Campo I, Emanuele E, et al. The -374 T/A polymorphism of the RAGE gene promoter in relation to severity of coronary atherosclerosis. Clin Chim Acta. 2005;354:111–116
  11. Falcone C, Emanuele E, D'Angelo A, et al. Plasma levels of soluble receptor for advanced glycation endproducts and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol. 2005;25:1032–1037
  12. Frosch M, Strey A, Vogl T, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000;43:628–637
  13. Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97:889–901
  14. Hofmann MA, Drury S, Hudson BI, et al. RAGE and arthritis: The G82S polymorphism amplifies the inflammatory response. Genes Immun. 2002;3:123–135
  15. Hori O, Brett J, Slattery T, et al. The receptor for advanced glycation endproducts (RAGE) is a cellular binding site for amphoterin: Mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system. J Biol Chem. 1995;270:25752–25761
  16. Huang JS, Guh JY, Chen HC, et al. Role of receptor for advanced glycation endproducts (RAGE) and the Jak/Stat-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem. 2001;81:102–113
  17. Hudson BI, Stickland MH, Futers TS, Grant PJ. Study of the -429T/C and -374T/A receptor for advanced glycation end products polymorphisms in diabetic and nondiabetic subjects with macrovascular disease. Diabetes Care. 2001;24:2004
  18. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation endproducts (RAGE)-mediated neurite outgrowth and activation of NF-κB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem. 1999;294:19919–19924
  19. Kanauchi M, Tsujimoto N, Hashimoto T. Advanced glycation endproducts in nondiabetic patients with coronary artery disease. Diabetes Care. 2001;24:1620–1623
  20. Kannel WB, McGee DL. Diabetes and cardiovascular disease: The Framingham Study. JAMA. 1979;241:2035–2038
  21. Kass DA, Shapiro EP, Kawaguchi M, et al. Improved arterial compliance by a novel advanced glycation endproduct crosslink breaker. Circulation. 2001;104:1464–1470
  22. Kirbis J, Milutinovic A, Steblovnik K, et al. The -429 T/C and -374 T/A gene polymorphisms of the receptor for advanced glycation endproducts gene (RAGE) are not risk factors for coronary artery disease in Slovene population with type 2 diabetes. Coll Antropol. 2004;28:611–616
  23. Kislinger T, Fu C, Huber B, et al. Nε (carboxymethyl)lysine modifications of proteins are ligands for RAGE that activate cell signaling pathways and modulate gene expression. J Biol Chem. 1999;274:31740–31749
  24. Kislinger T, Tanji N, Wendt T, et al. RAGE mediates inflammation and enhanced expression of tissue factor in the vasculature of diabetic apolipoprotein E null mice. Arterioscler Thromb Vasc Biol. 2001;21:905–910
  25. Kitauchi T, Yoshida K, Yoneda T, et al. Association between pentosidine levels and arteriosclerosis in patients receiving hemodialysis. Clin Exp Nephrol. 2004;8:48–53
  26. Lander HL, Tauras JM, Ogiste JS, et al. Activation of the receptor for advanced glycation end products triggers a MAP kinase pathway regulated by oxidant stress. J Biol Chem. 1997;272:17810–17814
  27. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation endproducts. J Biol Chem. 1997;272:16498–16506
  28. Little WC, Zile MR, Kitzman DW, et al. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail. 2005;11:191–195
  29. Maillard LC. Formation d'humus et de combustibles minéraux sans intervention de l'oxygène atmosphérique, des micro-organismes, des hautes températures ou fortes pressions. C R Acad Sci. 1912;154:1554–1556
  30. Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and carotid intima–media thickness in type 1 diabetes. N Engl J Med. 2003;348:2294–2303
  31. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of RAGE: A cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267:14998–15004
  32. Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by soluble receptor for AGE (sRAGE). Nat Med. 1998;4:1025–1031
  33. Petersson-Fernholm K, Forsblom C, Hudson BI, et al. The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes. 2003;52:891–894
  34. Rahbar S, Blumenfeld O, Ranney HM. Studies of an unusual hemoglobin in patients with diabetes mellitus. Biochem Biophys Res Commun. 1969;36:838–843
  35. Rammes A, Roth J, Goebeler M, et al. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem. 1997;272:9496–9502
  36. Rong LL, Yan SF, Wendt T, et al. RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways. FASEB J. 2004;18:1818–1825
  37. Sakaguchi T, Yan SF, Yan SD, et al. Arterial restenosis: Central role of RAGE-dependent neointimal expansion. J Clin Invest. 2003;111:959–972
  38. Schmidt AM, Vianna M, Gerlach M, et al. Isolation and characterization of binding proteins for advanced glycosylation endproducts from lung tissue which are present on the endothelial cell surface. J Biol Chem. 1992;267:14987–14997
  39. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321:405–412
  40. Taguchi A, Blood DC, Del Toro G, et al. Blockade of amphoterin/RAGE signalling suppresses tumor growth and metastases. Nature. 2000;405:354–360
  41. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med. 1993;329:977–986
  42. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837–853
  43. Vlassara H, Fuh H, Donnelly T, et al. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med. 1995;1:447–456
  44. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285:248–251
  45. Wautier JL, Schmidt AM. Protein glycation: A firm link to endothelial cell dysfunction. Circ Res. 2004;95:233–238
  46. Wautier JL, Paton RC, Wautier MP, et al. Increased adhesion of erythrocytes to endothelial cells in diabetes mellitus and its relation to vascular complications. N Engl J Med. 1981;305:237–242
  47. Wautier JL, Wautier MP, Schmidt AM, et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: A link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci U S A. 1994;91:7742–7746
  48. Wautier JL, Zoukourian C, Chappey O, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation endproducts blocks hyperpermeability in diabetic rats. J Clin Invest. 1996;97:238–243
  49. Wautier MP, Chappey O, Corda S, et al. Activation of NADPH oxidase by advanced glycation endproducts (AGEs) links oxidant stress to altered gene expression via RAGE. Am J Physiol. 2001;280:E685–E694
  50. Yan SSD, Wu ZY, Zhang HP, et al. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med. 2003;9:287–293
  51. Zhou Z, Wang K, Penn MS, et al. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation. 2003;107:2238–2243

PII: S1050-1738(05)00128-3

doi: 10.1016/j.tcm.2005.08.003

Trends in Cardiovascular Medicine
Volume 15, Issue 7 , Pages 237-243 , October 2005

Article Tools

* Image Usage & Resolution